Hit identification and optimization in virtual screening: practical recommendations based on a critical literature analysis.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  Journal of Medicinal Chemistry

• Publication date

  2013-06-07

• Fields of study

  Medicine, Chemistry, Computer Science

• Identifiers
  DOI 10.1021/jm301916bPMID 23688234PMCID PMC3772997
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Theoretical and Experimental Relationships between Percent Inhibition and IC50 Data Observed in High-Throughput Screening

  2013cited by this paper
• Rules for identifying potentially reactive or promiscuous compounds.

  2012cited by this paper
• admetSAR: A Comprehensive Source and Free Tool for Assessment of Chemical ADMET Properties

  2012cited by this paper
• Extending the Activity Cliff Concept: Structural Categorization of Activity Cliffs and Systematic Identification of Different Types of Cliffs in the ChEMBL Database

  2012cited by this paper
• Fragment-based approaches in drug discovery and chemical biology.

  2012cited by this paper
• Virtual compound screening in drug discovery.

  2012cited by this paper
• Recognizing Pitfalls in Virtual Screening: A Critical Review

  2012cited by this paper
• Exploring activity cliffs in medicinal chemistry.

  2012cited by this paper
• Discovery and optimization of a novel spiropyrrolidine inhibitor of β-secretase (BACE1) through fragment-based drug design.

  2012cited by this paper
• Design and synthesis of small molecule RhoA inhibitors: a new promising therapy for cardiovascular diseases?

  2011cited by this paper
• Probing the links between in vitro potency, ADMET and physicochemical parameters

  2011cited by this paper
• An improved malachite green assay of phosphate: mechanism and application.

  2011cited by this paper
• Combined Approach Using Ligand Efficiency, Cross-Docking, and Antitarget Hits for Wild-Type and Drug-Resistant Y181C HIV-1 Reverse Transcriptase

  2011cited by this paper
• State-of-the-art in ligand-based virtual screening.

  2011cited by this paper
• Identifying Actives from HTS Data Sets

  2011cited by this paper
• Design, Synthesis and Biological Evaluation of a Series of Novel Axl Kinase Inhibitors.

  2011cited by this paper
• Rational methods for the selection of diverse screening compounds.

  2011cited by this paper
• Exploring DNA Topoisomerase I Ligand Space in Search of Novel Anticancer Agents

  2011cited by this paper
• New substructure filters for removal of pan assay interference compounds (PAINS) from screening libraries and for their exclusion in bioassays.

  2010cited by this paper
• Complementarity Between a Docking and a High-Throughput Screen in Discovering New Cruzain Inhibitors

  2010cited by this paper
• Novel N-Substituted Benzimidazolones as Potent, Selective, CNS-Penetrant, and Orally Active M1 mAChR Agonists.

  2010cited by this paper
• Ligand efficiency indices for an effective mapping of chemico-biological space: the concept of an atlas-like representation.

  2010cited by this paper
• Small molecule correctors of F508del-CFTR discovered by structure-based virtual screening

  2010cited by this paper
• Discovery of highly selective inhibitors of human fatty acid binding protein 4 (FABP4) by virtual screening.

  2010cited by this paper
• Quo vadis, virtual screening? A comprehensive survey of prospective applications.

  2010cited by this paper
• Structure-based discovery of triphenylmethane derivatives as inhibitors of hepatitis C virus helicase.

  2009cited by this paper
• Comprehensive assessment of ADMET risks in drug discovery.

  2009cited by this paper
• Pharmacophore‐Based Discovery of Small‐Molecule Inhibitors of Protein–Protein Interactions between HIV‐1 Integrase and Cellular Cofactor LEDGF/p75

  2009cited by this paper
• Efficient drug lead discovery and optimization.

  2009cited by this paper
• Ligand binding efficiency: trends, physical basis, and implications.

  2008cited by this paper
• Comprehensive mechanistic analysis of hits from high-throughput and docking screens against beta-lactamase.

  2008cited by this paper
• Discovery of novel and cardioselective diltiazem-like calcium channel blockers via virtual screening.

  2008cited by this paper
• Virtual screening for novel quorum sensing inhibitors to eradicate biofilm formation of Pseudomonas aeruginosa

  2008cited by this paper
• Identification of High‐Affinity β‐Secretase Inhibitors Using Fragment‐Based Lead Generation

  2008cited by this paper
• Virtual screening and its integration with modern drug design technologies.

  2008cited by this paper
• The Scaffold Tree - Visualization of the Scaffold Universe by Hierarchical Scaffold Classification

  2007cited by this paper
• High-throughput screening assays for the identification of chemical probes.

  2007cited by this paper
• Search for Non-Nucleoside Inhibitors of HIV-1 Reverse Transcriptase Using Chemical Similarity, Molecular Docking, and MM-GB/SA Scoring

  2007cited by this paper
• Unbiasing Scoring Functions: A New Normalization and Rescoring Strategy

  2007cited by this paper
• Evaluating Virtual Screening Methods: Good and Bad Metrics for the "Early Recognition" Problem

  2007cited by this paper
• In silico pharmacology for drug discovery: applications to targets and beyond

  2007cited by this paper
• Discovery of inhibitors of the pentein superfamily protein dimethylarginine dimethylaminohydrolase (DDAH), by virtual screening and hit analysis.

  2007cited by this paper
• A critical assessment of docking programs and scoring functions.

  2006cited by this paper
• Fragment-based drug design: how big is too big?

  2006cited by this paper
• On Outliers and Activity Cliffs-Why QSAR Often Disappoints

  2006cited by this paper
• Exploration tools for drug discovery and beyond: applying SciFinder to interdisciplinary research.

  2005cited by this paper
• Can the pharmaceutical industry reduce attrition rates?

  2004cited by this paper
• Ligand efficiency: a useful metric for lead selection.

  2004cited by this paper
• Consideration of Molecular Weight during Compound Selection in Virtual Target-Based Database Screening

  2003cited by this paper
• A guide to drug discovery: Designing screens: how to make your hits a hit

  2003cited by this paper
• Molecular docking and high-throughput screening for novel inhibitors of protein tyrosine phosphatase-1B.

  2002cited by this paper
• The druggable genome

  2002cited by this paper
• Prediction of 'drug-likeness'.

  2002cited by this paper
• Molecular properties that influence the oral bioavailability of drug candidates.

  2002cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.

  2001cited by this paper
• Is There a Difference between Leads and Drugs? A Historical Perspective

  2001cited by this paper
• Drug-like properties and the causes of poor solubility and poor permeability.

  2000cited by this paper
• VolSurf: a new tool for the pharmacokinetic optimization of lead compounds.

  2000cited by this paper
• The maximal affinity of ligands.

  1999cited by this paper
• Chemical Similarity Searching

  1998cited by this paper
• Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings

  1997cited by this paper

• Learned Conformational Space and Pharmacophore Into Molecular Foundational Model.

  2026influential citation
• ProMol_Func: A Structure-Free Deep Learning Model for Virtual Screening

  2026cites this paper
• Deciphering anti-asthmatic components in loquat leaves (Eriobotrya japonica folium) by integrating network pharmacology, Mendelian randomization, and machine learning methods

  2026cites this paper
• Serial PNA-Transformer-Based Virtual Screening Identifies Nanomolar DYRK1A Inhibitors for Pancreatic Ductal Adenocarcinoma

  2026cites this paper
• Virtual Screening of FDA-Approved Compounds: Exploring New Alternatives for HIV Treatment.

  2026cites this paper
• Improving drug effectiveness using a second-generation artificial intelligence system based on the constrained-disorder principle to incorporate variability into drug design and administration: a perspective

  2026cites this paper
• Promiscuously bioactive compounds are prevalent in widely used commercial drug repurposing libraries.

  2025cites this paper
• Cache: Utilizing ultra-large library screening in Rosetta to identify novel binders of the WD-repeat domain of Leucine-Rich Repeat Kinase 2

  2025cites this paper
• RNAmigos2: accelerated structure-based RNA virtual screening with deep graph learning

  2025cites this paper
• Machine Learning-Based Virtual Screening for the Identification of Novel CDK-9 Inhibitors

  2025cites this paper
• In silico screening of multi-target drugs against Alzheimer s Disease: a repurposing approach

  2025influential citation
• Geometric-aware deep learning enables discovery of bifunctional ligand-based liposomes for tumor targeting therapy

  2025cites this paper
• Combining AlphaFold with Focused Virtual Library Design in the Development of Novel CCR2 and CCR5 Antagonists

  2025cites this paper
• Scaffold-Aware Generative Augmentation and Reranking for Enhanced Virtual Screening

  2025cites this paper
• Water-Based Pharmacophore Modeling in Kinase Inhibitor Design: A Case Study on Fyn and Lyn Protein Kinases

  2025cites this paper
• Harnessing antimalarial chemical space: the way forward

  2025cites this paper
• Protein–ligand data at scale to support machine learning

  2025cites this paper
• Fixing Truncation-Induced Mode Collapse in GFlowNets via Pruning Loss

  2025cites this paper
• High‐throughput screen identifies MAS9 as a novel inhibitor of the C‐type lectin receptor‐2 (CLEC‐2)–podoplanin interaction

  2025influential citation
• Industrial Automation using Artificial Intelligence

  2025cites this paper
• Discovery of novel STAT3 inhibitors with anti-breast cancer activity: structure-based virtual screening, molecular dynamics and biological evaluation.

  2025cites this paper
• Machine learning for RNA-targeting drug design

  2025cites this paper
• Computationally accelerated identification of P-glycoprotein inhibitors

  2025cites this paper
• Discovery of natural scaffolds as HER2 inhibitors for breast cancer: virtual screening, molecular dynamics, and biological characterization with selectivity profiling

  2025influential citation
• Ultrahigh-Throughput Virtual Screening Strategies against PPI Targets: A Case Study of STAT Inhibitors

  2025cites this paper
• A network-based protocol to prioritize compounds for biological testing: discovery of Anti-Staphylococcus aureus cacalol derivatives

  2025cites this paper
• A Machine Learning Platform for Isoform-Specific Identification and Profiling of Human Carbonic Anhydrase Inhibitors

  2025cites this paper
• WelQrate: Defining the Gold Standard in Small Molecule Drug Discovery Benchmarking

  2024cites this paper
• The Science and Art of Structure-Based Virtual Screening.

  2024cites this paper
• Virtual Screening of Peptide Libraries: The Search for Peptide-Based Therapeutics Using Computational Tools

  2024cites this paper
• Accelerated hit identification with target evaluation, deep learning and automated labs: prospective validation in IRAK1

  2024cites this paper
• A virtual library of small molecules mimicking dipeptides

  2024cites this paper
• Computationally accelerated identification of P-glycoprotein inhibitors

  2024cites this paper
• HBCVTr: an end-to-end transformer with a deep neural network hybrid model for anti-HBV and HCV activity predictor from SMILES

  2024cites this paper
• Revolutionizing Drug Discovery: A Comprehensive Review of AI Applications

  2024cites this paper
• Computer-Aided Drug Discovery and Design: Recent Advances and Future Prospects.

  2024cites this paper
• Leveraging multiple data types for improved compound-kinase bioactivity prediction

  2024influential citation
• Targeting the hSSB1-INTS3 Interface: A Computational Screening Driven Approach to Identify Potential Modulators

  2024cites this paper
• Discovering New Horizons: A Systematic Review on Artificial Intelligence Applications in Drug Discovery and Development.

  2024cites this paper
• Graph Neural Networks and Molecular Docking as Two Complementary Approaches for Virtual Screening: A Case Study on Cruzain

  2024cites this paper
• Blocker-SELEX: a structure-guided strategy for developing inhibitory aptamers disrupting undruggable transcription factor interactions

  2024cites this paper
• Drug Discovery Tools and In Silico Techniques: A Review

  2024influential citation
• Expedient synthesis of 8-membered azasultams: a combined synthetic, DFT, and in vitro study

  2024cites this paper
• Leveraging Machine Learning and AlphaFold2 Steering to Discover State-Specific Inhibitors Across the Kinome

  2024influential citation
• Inhibitors of Immune Checkpoints: Small Molecule- and Peptide-Based Approaches

  2024cites this paper
• Discovery of allosteric regulators with clinical potential to stabilize alpha-L-iduronidase in mucopolysaccharidosis type I

  2024cites this paper
• A bottom‐up approach identifies the antipsychotic and antineoplastic trifluoperazine and the ribose derivative deoxytubercidin as novel microglial phagocytosis inhibitors

  2024cites this paper
• Machine Learning Models Identify Inhibitors of New Delhi Metallo-β-lactamase

  2024cites this paper
• Review of the impact of fragment-based drug design on PROTAC degrader discovery

  2024cites this paper
• Ligand-Based Compound Activity Prediction via Few-Shot Learning

  2024cites this paper
• Stem cell-based approaches for developmental neurotoxicity testing

  2024cites this paper
• Deep phenotypic profiling of neuroactive drugs in larval zebrafish

  2024cites this paper
• Anti-inflammation is an important way that Qingre-Huazhuo-Jiangsuan recipe treats acute gouty arthritis

  2023cites this paper
• SARS-CoV-2 external structures interacting with nanospheres using docking and molecular dynamics

  2023influential citation
• A flexible data-free framework for structure-based de novo drug design with reinforcement learning

  2023cites this paper
• Perspectives on Ligand/Protein Binding Kinetics Simulations: Force Fields, Machine Learning, Sampling, and User-Friendliness

  2023cites this paper
• Computational screening of potential bromodomain-containing protein 2 inhibitors for blocking SARS-CoV-2 infection through pharmacophore modeling, molecular docking and molecular dynamics simulation

  2023cites this paper
• In Silico Screening of Inhibitors of the Venezuelan Equine Encephalitis Virus Nonstructural Protein 2 Cysteine Protease

  2023cites this paper
• Improving molecular machine learning through adaptive subsampling with active learning

  2023cites this paper
• Keeping pace with the explosive growth of chemical libraries with structure‐based virtual screening

  2023cites this paper
• Automation of Drug Discovery through Cutting-edge In-silico Research in Pharmaceuticals: Challenges and Future Scope.

  2023cites this paper
• Fundamentals of Molecular Docking and Comparative Analysis of Protein–Small-Molecule Docking Approaches

  2023cites this paper
• Discovery of High-Affinity Amyloid Ligands Using a Ligand-Based Virtual Screening Pipeline

  2023cites this paper
• An interaction-based drug discovery screen explains known SARS-CoV-2 inhibitors and predicts new compound scaffolds

  2023cites this paper
• Identification of Potent Inhibitors Targeting EGFR and HER3 for Effective Treatment of Chemoresistance in Non-Small Cell Lung Cancer

  2023cites this paper
• SARS-CoV2 billion-compound docking

  2023cites this paper
• Using macromolecular electron densities to improve the enrichment of active compounds in virtual screening

  2023cites this paper
• Pharmacological Chaperones and Protein Conformational Diseases: Approaches of Computational Structural Biology

  2023cites this paper
• Sequence-based drug design as a concept in computational drug design

  2023cites this paper
• Past, Present, and Future Perspectives on Computer-Aided Drug Design Methodologies

  2023cites this paper
• Where developmental toxicity meets explainable artificial intelligence: state-of-the-art and perspectives

  2023cites this paper
• Structure-based pharmacophore modeling 1. Automated random pharmacophore model generation.

  2023cites this paper
• BEAR: A Novel Virtual Screening Method Based on Large-Scale Bioactivity Data

  2023cites this paper
• A Review on Artificial Intellegence in Drug Discovery & Pharmaceutical Industry

  2023cites this paper
• Chemokine Receptors—Structure-Based Virtual Screening Assisted by Machine Learning

  2023cites this paper
• Exploring the Fatty Acid Binding Pocket in the SARS-CoV-2 Spike Protein - Confirmed and Potential Ligands

  2023cites this paper
• Target-Free Compound Activity Prediction via Few-Shot Learning

  2023cites this paper
• Integrated systems biology approach identifies gene targets for endothelial dysfunction

  2023cites this paper
• Integration of molecular modelling and in vitro studies to inhibit LexA proteolysis

  2023cites this paper
• Identification of potential inhibitors of Mtb InhA: a pharmacoinformatics approach

  2023cites this paper
• Streamlining pipeline efficiency: a novel model-agnostic technique for accelerating conditional generative and virtual screening pipelines

  2023cites this paper
• Intelligent Computing: The Latest Advances, Challenges and Future

  2022cites this paper
• An Integrated Machine Learning Model To Spot Peptide Binding Pockets in 3D Protein Screening

  2022cites this paper
• Molecular docking-based virtual screening: Challenges in hits identification for Anti-SARS-Cov-2 activity

  2022influential citation
• In silico network-based screening reveals candidates for endothelial dysfunction therapy

  2022cites this paper
• Small Molecules as Toll-like Receptor 4 Modulators Drug and In-House Computational Repurposing

  2022cites this paper
• Two-Track Virtual Screening Approach to Identify the Dual Inhibitors of Wild Type and C481S Mutant of Bruton's Tyrosine Kinase

  2022cites this paper
• Recent Updates on Bacterial Secondary Metabolites to Overcome Antibiotic Resistance in Gram-Negative Superbugs: Encouragement or Discontinuation?

  2022cites this paper
• A machine learning model trained on a high-throughput antibacterial screen increases the hit rate of drug discovery

  2022cites this paper
• Identification of natural product inhibitors of de novo lipogenesis enzymes as an anti-cancer strategy: An in silico approach

  2022cites this paper
• Identifying RO9021 as a Potential Inhibitor of PknG from Mycobacterium tuberculosis: Combinative Computational and In Vitro Studies

  2022cites this paper
• Nardosinone and aurantio-obtusin, two medicine food homology natural compounds, are anti-influenza agents as indicated by transcriptome signature reversion.

  2022cites this paper
• Amelioration of Alzheimer’s disease pathology by mitophagy inducers identified via machine learning and a cross-species workflow

  2022influential citation
• The Impact of Software Used and the Type of Target Protein on Molecular Docking Accuracy

  2022cites this paper
• Discovery of novel drug-like antitubercular hits targeting the MEP pathway enzyme DXPS by strategic application of ligand-based virtual screening

  2022cites this paper
• Combinatorial Virtual Screening Revealed a Novel Scaffold for TNKS Inhibition to Combat Colorectal Cancer

  2022cites this paper
• Ligand Binding Prediction Using Protein Structure Graphs and Residual Graph Attention Networks

  2022cites this paper
• Structure-Based Discovery of Lipoteichoic Acid Synthase Inhibitors

  2022cites this paper
• Phenotypic Screening for Small Molecules that Protect β-Cells from Glucolipotoxicity

  2022cites this paper
• In Silico Approaches for Drug Discovery Focus on Virtual Screenings

  2022cites this paper